M&A Acquirer Playbook

GLOBUS MEDICAL INC acquisition history.

Every deal, price, and strategic rationale.

Company GLOBUS MEDICAL INC

SEC CIK 0001237831

Tracked filings EDGAR · 8-K

Total deals tracked

Disclosed 8-K acquisitions, 2015 — present.

Aggregate disclosed value

$400M

Roughly $400 million in cash deals plus the all-stock NuVasive merger across 6 disclosed transactions — building a global musculoskeletal company.

Active acquisition years

2015 · 2016 · 2018 · 2019 · 2023 · 2025

punctuated by the transformational 2023 NuVasive merger.

Primary sectors

Spine & musculoskeletal devices , joint reconstruction (StelKast), neuromodulation (Nevro) and enabling-technology software (Nemaris / Surgimap)

NuVasive, Alphatec international, Branch Medical.

Verified 6 deals on this page · sourced from SEC filings

All cross-references covered.

Timeline

6 deals, $400M deployed.

Plotted by close date where disclosed, otherwise announcement. Click any marker to jump to the deal entry.

The playbook

The rationale that repeats.

Three patterns show up across GLOBUS MEDICAL's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the individual deals below are the evidence.

Acquisition criteria

One transformational merger, many bolt-ons.

Globus built itself organically for years, then made the all-stock NuVasive merger in 2023 the defining moment of its history, roughly doubling its scale to create a leading global musculoskeletal company. Around that anchor it has layered targeted cash acquisitions rather than a steady stream of tuck-ins.

NuVasiveNevro Corp.Alphatec's International BusinessBranch Medical GroupStelKast

Capital deployment

Expanding beyond core spine into adjacent musculoskeletal markets.

Each deal pushed Globus into a new arena: StelKast opened total joint arthroplasty (knee and hip), Nevro added neuromodulation for chronic pain, and Nemaris's Surgimap brought surgical-planning software. Management frames these as steps toward becoming the preeminent musculoskeletal technology company.

NuVasiveNevro Corp.Alphatec's International BusinessBranch Medical GroupStelKast

Integration approach

Buying scale, technology and supply chain.

Globus has used M&A to acquire international reach (Alphatec's overseas operations, which roughly doubled its international sales), to vertically integrate manufacturing (Branch Medical, a related-party supplier since 2005), and to add enabling technology (Surgimap and NuVasive's Pulse platform) — combining commercial scale with differentiated technology.

NuVasiveNevro Corp.Alphatec's International BusinessBranch Medical GroupStelKast

Deal book · 6 acquisitions

The full deal book.

6 acquisitions. Click any row to see the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.

NuVasive, Inc. is a San Diego-based global medical technology company focused on spine surgery, known for its lateral access procedures and the Pulse enabling-technology platform spanning surgical planning, navigation, imaging and intraoperative neuromonitoring.

Why it was attractive

01 Complementary spine portfolio and the Pulse enabling-technology platform
02 roughly doubling Globus Medical's scale and adding lateral-access expertise and broader commercial reach

Capabilities acquired

spine implantslateral access spine surgerysurgical planningnavigationimagingintraoperative neuromonitoringenabling technology

Our combination with NuVasive is a defining moment in our company's history. I'm incredibly proud of the strong legacy we've built at Globus Medical, and I look forward to delivering on the many opportunities for our surgeon customers and their patients as a combined company.

David Paul Executive Chairman, Globus Medical

The combination with Globus Medical is highly transformative-bringing together two leading companies with a shared vision to change the lives of more patients around the globe. I look forward to helping the combined organization transform the future of surgery.

Chris Barry former Chief Executive Officer, NuVasive

Post-close · earnings-call commentary

Dan Scavilla, President and CEO, Globus Medical (Sept 1, 2023 completion release): "We're thrilled to begin our journey together to create a leading global musculoskeletal company. With a relentless focus on changing patient lives, we're combining our differentiated portfolios and talented teams to reach more customers as we advance spine and orthopedic care globally."

Deal value

Stock-for-stock merger at a fixed exchange ratio of 0.75 Globus Medical share per NuVasive share; pro forma ownership ~72% Globus Medical / ~28% NuVasive shareholders

Terms

AnnouncedFeb 2023

ClosedSep 2023

StructureMerger

Considerationall stock

Deal facts

GeographySan Diego, California, USA

SegmentSpine & musculoskeletal — spine implants and enabling technology

Integration unitCombined under Globus Medical (NYSE: GMED), with David Paul as Executive Chairman and Dan Scavilla as CEO

Integration timelineAnnounced February 9, 2023; completed September 1, 2023.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall stock.

SEC 8-K · NuVasive

Nevro Corp. is a Redwood City, California global medical device company delivering comprehensive solutions for the treatment of chronic pain, known for its high-frequency (HFX) spinal cord stimulation technology.

Why it was attractive

01 World-class
02 differentiated high-frequency neuromodulation technology opening a roughly $2 billion chronic-pain market opportunity for Globus

Capabilities acquired

spinal cord stimulationhigh-frequency (HFX) neuromodulationchronic pain management devices

This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions.

Dan Scavilla President and CEO, Globus Medical

We are thrilled to join Globus Medical as this will allow us to reach more patients globally with clinically proven, innovative products that significantly reduce the burden of chronic pain.

Kevin Thornal CEO and President, Nevro Corp.

Post-close · earnings-call commentary

Dan Scavilla, President and CEO, Globus Medical (April 3, 2025 completion release): "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much needed treatment option to patients suffering from chronic pain."

Deal value

$250M

approximately $250 million total equity value ($5.85 per share in cash)

Terms

AnnouncedFeb 2025

ClosedApr 2025

StructureFull acquisition

Considerationall cash

Financials

Cash impact / synergiesGlobus expects its scale and operational discipline to optimize Nevro's financial performance and drive enhanced profitability.

Deal facts

GeographyRedwood City, California, USA

SegmentNeuromodulation — chronic pain management

Integration unitIntegrated into Globus Medical; Nevro common stock ceased trading on the NYSE on April 3, 2025

Integration timelineAnnounced February 6, 2025; completed April 3, 2025.

Not disclosed in filing Target revenue / EBITDA

Fundingall cash.

SEC 8-K · Nevro Corp.

The international operations and distribution channels of Alphatec Holdings, Inc. (Nasdaq: ATEC), covering direct and distributor sales channels across Asia, Europe and the Americas, including subsidiaries in the UK, Italy, the Netherlands, France, Germany, Hong Kong, Japan, Brazil, China, Singapore and Australia.

Why it was attractive

01 Immediate access to Japan and other key international markets
02 roughly doubling Globus's international sales and adding an established distributor network

Capabilities acquired

international spine distribution channelsdirect and distributor sales networks across AsiaEurope and the Americas

Strategically, this acquisition gives us immediate access to Japan and increased presence and penetration in other key geographies, and significant scale, roughly doubling our international sales. In addition, we will be acquiring a talent pool of international sales professionals as well as an extensive network of international distributors.

David Paul Chairman and CEO, Globus Medical

Deal value

$80M

approximately $80 million in cash (plus a 5-year senior secured credit facility of up to $30 million extended to Alphatec)

Terms

AnnouncedJul 2016

ClosedJul 2016

StructureCarve-out

Considerationall cash

Financials

Target revenue / EBITDAApproximately $71 million in 2015 international sales (and $15.6 million in Q1 2016)

Cash impact / synergiesExpected to be marginally accretive in 2017 and to add up to 8 cents of incremental non-GAAP diluted EPS in 2018 and beyond.

Deal facts

GeographyInternational — Asia, Europe and the Americas (acquired by Globus Medical Ireland, Ltd.)

SegmentSpine — international distribution and operations

Integration unitAcquired through Globus Medical Ireland, Ltd.; includes a 5-year supply agreement under which Alphatec supplies products to Globus during transition

Integration timelineAnnounced July 26, 2016 (8-K filed July 27, 2016); closing expected by October 2016.

Fundingall cash.

SEC 8-K · Alphatec's International Business

Branch Medical Group, Inc. (BMG) is an Audubon, Pennsylvania manufacturer of high-precision medical devices that had been a third-party supplier to Globus Medical since 2005.

Why it was attractive

01 Vertical integration of a long-standing precision-manufacturing supplier already embedded in Globus's supply chain since 2005

Capabilities acquired

high-precision medical device manufacturingcontract manufacturing of spine implants and instruments

On February 24, 2015, Globus Medical, Inc. entered into an Agreement and Plan of Merger with Branch Medical Group, Inc. ... The aggregate consideration for all of the outstanding equity interests of BMG is approximately $52.9 million in cash, subject to customary adjustment after closing for certain working capital items and indebtedness.

Globus Medical 8-K dated March 2, 2015 (Item 1.01)

Deal value

$57.0M

approximately $57.0 million in cash plus $5.3 million deferred consideration (aggregate ~$52.9 million disclosed at signing, subject to working-capital adjustment)

Terms

AnnouncedMar 2015

ClosedMar 2015

StructureMerger

Considerationall cash

Deal facts

GeographyAudubon, Pennsylvania, USA

SegmentSpine — precision medical device manufacturing

Integration unitMerged as a wholly-owned subsidiary of Globus Medical

Integration timelineSigned February 24, 2015 (8-K filed March 2, 2015); closed March 11, 2015.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash.

SEC 8-K · Branch Medical Group

StelKast, Inc. is a privately held company that designs, manufactures and distributes orthopedic implants for knee and hip replacement surgeries.

Why it was attractive

01 Entry platform into the Total Joint Arthroplasty (knee and hip) market with an established implant portfolio

Capabilities acquired

knee and hip replacement implantstotal joint arthroplastyorthopedic implant design and manufacturing

The StelKast acquisition should serve as a platform to expand our products and services into the Total Joint Arthroplasty market. Globus Medical's proven product development engine and history of innovation, when combined with our computer assisted technologies in Imaging, Navigation and Robotics, have the potential to improve clinical care for joint arthroplasty patients and create value for shareholders.

David Paul Executive Chairman, Globus Medical

Deal value

$28.4M

approximately $28.4 million net assets (about $24.1 million cash at closing plus up to $4.3 million contingent consideration based on product-sales milestones)

Terms

AnnouncedAug 2019

ClosedApr 2019

StructureAsset purchase

Considerationall cash

Deal facts

GeographyUSA

SegmentOrthopedics — joint reconstruction (knee and hip)

Integration unitIntegrated into Globus Medical's musculoskeletal portfolio

Integration timelineAcquired in Q2 2019; disclosed in the Q2 2019 earnings release (8-K dated August 1, 2019) and the Q2 2019 Form 10-Q Business Combinations note.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash.

SEC 8-K · StelKast

Nemaris, Inc. is a privately held company that markets and develops Surgimap, a surgical planning software platform; substantially all of the acquired value was in developed technology.

Why it was attractive

01 Adds the Surgimap surgical-planning software and its developed technology to Globus's enabling-technology suite

Capabilities acquired

surgical planning softwareSurgimap platformpreoperative planning and surgical simulation

On September 5, 2018, we acquired Nemaris, Inc. ("Nemaris"), a privately held company that markets and develops Surgimap, a surgical planning software platform. ... the Nemaris Acquisition was accounted for as an asset purchase. We allocated the consideration paid of $15.2 million on a pro rata basis to the assets acquired.

Globus Medical Q2 2019 Form 10-Q, Business Combinations note

Deal value

$15.2M

approximately $15.2 million (asset purchase)

Terms

AnnouncedSep 2018

ClosedSep 2018

StructureAsset purchase

Considerationall cash

Deal facts

GeographyUSA

SegmentEnabling technology — surgical planning software

Integration unitIntegrated into Globus Medical's enabling-technology / software portfolio

Integration timelineClosed September 5, 2018; disclosed in the Form 10-Q Business Combinations note.

Not disclosed in filing Target revenue / EBITDA · Cash impact / synergies

Fundingall cash.

SEC 8-K · Nemaris

End of deal book

6 acquisitions · $400M deployed ·2015 — present

VectorShift for deal teams

Put VectorShift to work
on every deal.

VectorShift reads the documents your team actually works on — CIMs, management decks, filings, expert calls, portfolio reports — and returns structured, sourced analysis in minutes, not weeks.

Request a demo

6 deals, $400M deployed.

The rationale that repeats.

One transformational merger, many bolt-ons.

Expanding beyond core spine into adjacent musculoskeletal markets.

Buying scale, technology and supply chain.

The full deal book.

Put VectorShift to workon every deal.

Put VectorShift to work
on every deal.